We have found that the platelet-derived growth factor receptor (PDGFR)/Abl signaling pathway is upregulated as a determinant of the acquisition of resistance to estrogen deprivation in vitro. We aimed to determine its clinical relevance in aromatase inhibitor (AI)-resistant breast cancer.
introduction
The majority of breast cancer patients at primary diagnosis (80%) have breast tumors that express the estrogen receptor (ER) and require estrogen for their growth. This observation has been exploited clinically by the development of endocrine agents, which can target the interaction between the ER and estrogen by eliciting ER degradation, blocking estrogen synthesis or impeding the interaction of estrogen with the ER [1] [2] [3] . Tamoxifen has been the most commonly prescribed drug both for the treatment of advanced disease and as adjuvant therapy after surgery, prolonging both disease-free and overall survival. However, aromatase inhibitors (AIs) have been shown to have superior efficacy to tamoxifen in both early and advanced breast cancer with response rates of 30%-50% as first-line metastatic therapy [4] . Despite these advances, endocrine therapy is limited by relapse or inevitable disease progression in the metastatic setting.
In recent years, several studies have been published reporting on molecular changes associated with the acquisition of resistance to tamoxifen treatment in clinical samples. Our group reported a substantial loss of ER and PgR in the relapse samples [5] and identified the emergence of relationships between ER, p-p38 and p-ERK at the point of relapse [6] together with an increase in Her2 in a small group of patients. There is, however, a paucity of data investigating the role of biomarkers associated with response to AI treatment and focusing on their specific changes associated with resistance.
Preclinical and clinical studies provide support for mechanisms that involve cross-talk between ER and growth factor signaling pathways, including ERBB2/HER2 [2, 7, 8] , but the latter is only overexpressed in ∼10% of ER+ patients and is infrequently overexpressed with the acquisition of resistance [9] , indicating that alternative underlying molecular events remain to be discovered. To identify the molecular mechanisms associated with resistance to estrogen deprivation, we previously assessed the temporal changes in gene expression during adaptation to long-term culture of MCF7 human breast cancer cells in the absence of estradiol (E2) [(long-term estrogen deprived (LTED)], modeling resistance to an AI. Surprisingly, platelet-derived growth factor (PDGF)/Abl signaling was the top adaptive pathway at the point of resistance (P = 1.15E − 07). Cell proliferation of LTED cells was suppressed in the presence and absence of E2 by either siRNA knockdowns of PDGFRβ (PDGFR, PDGF receptor) and/or Abl or the tyrosine kinase inhibitor nilotinib. Moreover, nilotinib, a PDGFR/Abl inhibitor also suppressed ER-mediated transcription by destabilizing the ER and reducing the recruitment of AIB1, a major coactivator of the ER to the promoter of the estrogen-responsive gene GREB1 [10, 11] . This highlights the role of PDGFR/Abl signaling in resistance to estrogen deprivation, but currently there is limited evidence for it playing a role clinically.
PDGFRα and β contain an intracellular tyrosine kinase domain whose activation is dependent on the binding of PDGF ligands. Autocrine or paracrine receptor activation causes the stimulation of several intracellular pathways, leading to cell proliferation and survival as well as promoting angiogenesis and has been shown to be involved in cancer growth [12] . Several cancer entities such as glioblastomas [13] , gastrointestinal stromal tumors [14] and dermatofibrosarcoma protuberans [15] have been described to proliferate in response to PDGFR stimulation. In breast cancer, stromal expression of PDGFRβ has been associated with a poor prognosis [16] and PDGFR has been associated previously with anti-estrogen resistance [17] .
Abl is an Src-like nonreceptor protein kinase that acts downstream of the PDGFR and is involved in the regulation of cell proliferation, apoptosis, adhesion, cell migration and stress responses [18, 19] . Recent studies suggest that Abl kinases are activated in breast cancer cells and that this activation promotes cell invasion [20, 21] . Moreover it has been shown that ER transcriptional activity and protein stability can be regulated by Abl via phosphorylation of the ER at tyrosine 52 and 219 [22] . Activation of Abl and interaction with the ER have also been linked to enhanced resistance to tamoxifen in a breast cancer cell model [23] . Recently, Abl has been shown to phosphorylate AIB1, a nuclear coactivator for ER, providing evidence for the role of Abl in modulating ER function [24] .
The clinical importance of the PDGFR/Abl signaling pathway in the development of AI-resistant breast cancer has not been reported. This is largely due to the poor availability of matched tumor biopsies at presentation and after the development of resistance. We have previously created a collection of such specimens and characterized it for changes in ER and other directly related biomarkers [25] . We therefore used this novel resource to assess PDGFRα, PDGFRβ and Abl protein expression levels and their relevant changes in paired samples ( pre-and post-treatment) of a cohort of 45 breast cancer patients who were treated with an AI either in the primary or metastatic setting and relapsed on this treatment.
materials and methods

patient selection
For this study, clinical records of the Royal Marsden Hospital (London) were reviewed and patients were selected who had ER-positive disease, had been treated with an AI (anastrozole, letrozole or exemestane) for primary or advanced breast cancer and subsequently relapsed on this treatment. Patients who received an AI for <1 month until treatment failure were excluded. Archival formalin-fixed paraffin-embedded tissue from primary surgery or advanced disease and post-AI treatment was retrieved from eligible patients who had been diagnosed between 1980 and 2005 and were treated with an AI from 1998 to 2009. Patient data were obtained retrospectively using clinical records, and time to AI treatment failure (TTF) was defined as time from commencement of AI treatment until progression of disease, death or termination of treatment due to adverse effects.
immunohistochemistry
Immunohistochemical (IHC) staining was carried out on full sections. ER, PgR and Ki67 staining was carried out as previously described [26, 27] . Staining intensity for ER and PgR was analyzed using the Histo-score (H-score), which creates a score from 0 to 300 as a sum of the percentages of cells staining weakly (1+), moderately (2+) and strongly (3+) [28] . The percentage of positively stained nuclei was calculated for Ki67. The Herceptest (DakoCytomation, Carpinteria, CA) and FISH (Vysis Pathvysion, Abbott Laboratories, Abbott Park, IL) were used to obtain the HER2 status, according to manufacturers' instructions. Staining for PDGFRα and PDGFRβ was carried out as described [29] and Abl staining was done accordingly. Sections were deparaffinized, rehydrated and antigen retrieval was carried out using EDTA pH6. Sections were incubated in peroxidase blocking solution, blocked in goat serum. Slides were then incubated with primary antibody [anti-PDGFRα (ab35765) (Abcam, Cambridge, UK), anti-PDGFRβ (3169) (Cell Signaling, Danvers, MA) and anti-c-Abl (Ab-1) (Thermo Scientific, Epsom, UK)]. The streptavidinbiotin DAB method was used to develop IHC staining. Slides were counterstained with Meyer's hematoxylin. For all IHC staining methods, appropriate positive and negative controls were carried out with each batch. The H-score was assessed for PDGFRα/β and Abl staining of tumor cells. Staining intensity of tumor-associated fibroblasts was scored independently for PDGFRα and β by assigning a score from 0 to 3 (0 = negative, 1 = weak, 2 = moderate, 3 = strong). Scorers were blinded to patient outcome and a separate observer independently scored ∼20% of specimens. Spearman's rank correlation was employed to assess relationships between the different markers as well as TTF.
results
patient characteristics
Paired tissue specimens before and after relapse on AI treatment were identified for 45 patients. Due to insufficient malignant tissue in a small number of samples, paired analyses were possible for PDGFRα, PDGFRβ and Abl in 44, 45 and 43 patients, respectively. The clinical characteristics are indicated in Table 1 and the median age at diagnosis was 54 years (range 33-77 years). The median TTF was 69 weeks (range 5-310 weeks). Pre-treatment specimens were from the primary tumor for 19 patients (42.2%) and from recurrent disease before the start of the AI treatment for 26 patients (57.8%). All pretreatment specimens were ER-positive, and 28 cases (62.2%) also showed PgR positivity.
tumor PDGFRα, β and Abl staining before and after relapse on AI treatment expression of PDGFRα and PDGFRβ in fibroblasts before and after relapse on AI treatment
The expression of PDGFRα and PDGFRβ was also examined in stromal fibroblasts. In the pre-treatment samples (44), PDGFRα expression was evident in only 8 (18%) and the staining was weak. Of the 44 post-treatment AI-relapse cases, 13 (30%) showed an increase in the expression of stromal PDGFRα and 3 (7%) a decrease.
Expression of PDGFRβ was similarly assessed. Of the 45 pre-treatment samples, 9 patients (20%) showed strong, and 11 (24%) moderate, staining of PDGFRβ. The remaining 25 were either weak (16) (36%) or negative (9) (20%). After AI relapse, strong PDGFRβ expression was evident in 14 (31%) cases, while moderate staining was observed in 16 (36%). Of note, the number of cases with weak or negative staining decreased to 13 (29%) and 2 (4%), respectively.
correlations before AI treatment
Significant positive correlations could be observed between the expression of PDGFRα in tumor cells and stromal fibroblasts in the pre-AI-treatment breast cancer samples. Similar significant associations were detected for PDGFRβ expression in tumor cells and fibroblasts ( Table 2 ). None of the other assessed markers (ER, PgR, Ki67 and Her2) showed a significant correlation with PDGFRα, β or Abl expression before AI treatment.
correlations after AI treatment
In the post-AI-treatment samples, similar significant positive correlations could be observed between the tumor cell and stromal expression of PDGFRα as well as PDGFRβ (Table 3) . A positive correlation of Abl and tumor cell PDGFRα expression was detectable in the relapse samples. In contrast, a significant association between Abl and PDGFRβ expression could not be observed. Moreover, there were no significant correlations detectable with ER, PgR and Her2 expression. In this cohort of patients, the level of Ki67 (a marker of proliferation) was increased in the relapse sample (mean 9.8% versus 16.4%; detailed analyses have been published separately by Arnedos et al. [25] ) and the expression of PDGFRα was significantly correlated with Ki67 levels at the point of relapse. This could be observed for the tumor as well as the stromal PDGFRα expression [Spearman's rank order correlation coefficient (Rs) 0.39, P = 0.011; Rs 0.44, P = 0.003, respectively].
correlations between changes in biomarker expression
The pre-and post-AI-treatment expression of stromal and tumor cell PDGFRα as well as stromal and tumor PDGFRβ were significantly correlated and changes in these respective markers were similarly associated ( Table 4 ). The changes in Abl expression between the pre-treatment and relapse samples correlated positively with changes in the expression of ER (Table 4 ). In addition, changes in stromal PDGFRβ expression were also correlated with changes in ER. Correlations of changes in Ki67 levels revealed a significant positive association with changes in stromal PDGFRα expression and a trend toward significance in changes in tumor PDGFRα (Table 4) .
correlations with patient outcome
In this particular cohort of breast cancer patients, the median TTF on an AI was 69 weeks with a range of 5-310 weeks. Of the biomarkers tested on breast cancer tumor cells before treatment, none had a predictive value of clinical benefit from original articles Annals of Oncology the AI. However, at the time of relapse on the AI, expression levels of PDGFRβ revealed a trend toward an inverse correlation with TTF (Rs −0.28, P = 0.066) ( Table 5) . Pretreatment expression of PDGFRβ within tumor stromal fibroblasts was predictive of a poor clinical outcome (Rs −0.337, P = 0.028). Similarly, high levels of PDGFRβ within tumor stromal fibroblasts at the point of relapse on AI treatment also associated with a shorter TTF (Rs −0.31, P = 0.046) ( Table 5) .
discussion
In recent years, large trials have shown the superiority of AIs over tamoxifen in the treatment of ER+ breast cancer patients [4, 30] . However, a proportion of patients treated in the adjuvant setting will present with recurrent disease. In contrast, most of the patients treated in the metastatic setting will develop resistance to AI-treatment even after an initial response. It is therefore of paramount importance to identify biomarkers predictive of response to AI treatment and to determine the molecular mechanisms underlying the development of endocrine resistance, in order to provide novel treatment strategies. To date, there are no reports published investigating changes in biomarkers between patients with AI-sensitive and -resistant advanced breast cancer. As such, a cohort of patients who had been treated with an AI and subsequently presented with recurrent disease was selected. The reported study focuses on changes in the PDGFR/Abl signaling pathway and its association with TTF. The work extends our identification of this as the top adaptive pathway at the point of resistance in a study of changes in gene expression during adaptation to long-term culture of MCF7 human breast cancer cells in the absence of E2 (LTED). The relevance of these in vitro findings was confirmed in data from 81 patients before and after 2 weeks of neoadjuvant AI therapy: the PDGF signaling pathway showed that PDGFRβ gene expression levels increased substantially after 2 weeks on AI treatment, and pretreatment expression of PDGFRβ was associated with a poor response to AIs [11] . These findings suggest that this pathway may be associated with de novo or acquired resistance to endocrine therapy and are strongly supported by the data in the current report.
The IHC analyses reported here reveal substantial increases in PDGFRα, β and Abl expression during the development of resistance to an AI. Other studies have focused on determining the expression of PDGFRα, β or Abl in normal breast tissue, Figure 1 . Changes in tumor PDGFRα, PDGFRβ and Abl expression. Full sections of breast cancer specimens before and after aromatase inhibitor treatment were stained for the expression of PDGFRα, PDGFRβ and Abl. Expression levels were assessed using an H-score.
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benign lesions and primary tumors [23, 31, 32] as well as tumor fibroblasts [16] . The pre-treatment expression levels in our cohort were comparable with the expression frequencies published. However, many reports only focused on qualitative scoring methods ( positive versus negative). In this study, the semi-quantitative H-score was used to determine better any changes in biomarker expression levels. IHC analyses of phosphorylated proteins were not conducted because of the original articles Annals of Oncology loss of phospho-staining that can occur during routine fixation of resected specimens [33] . Although the patient cohort consisted of subsets of patients who were treated with an AI for primary breast cancer or after relapse on tamoxifen, there was no detectable difference in pre-AI-treatment expression for any of the markers between the subsets (supplementary Figure S1 , available at Annals of Oncology online). However, we cannot discount the possibility that PDGFR/Abl signaling may be also associated with tamoxifen resistance.
Staining of tumor fibroblasts for PDGFRα and β was assessed to evaluate paracrine effects between tumor cells and fibroblasts and their potential involvement in the development of resistance. It has been reported that in breast cancer fibroblasts, PDGFRβ expression outweighed PDGFRα in a large unselected cohort of breast tumors [16] . In our cohort of paired endocrine-sensitive and -resistant specimens, a similar expression pattern was observed and the predictive value of fibroblast PDGFRβ expression on outcome was confirmed [16] .
In addition, the post-treatment expression of PDGFRβ in tumor fibroblasts was correlated with a shorter TTF, while the correlation of tumor cell PDGFRβ expression and TTF bordered on statistical significance, supporting the relevance of PDGFRβ in the development of disease progression.
Tumor cell and fibroblast expression were significantly correlated with each other for both of the PDGFRs in pretreatment and in relapse samples. This is of special interest due to the fact that breast tumor cells express PDGF ligands that promote cell angiogenesis as well as tumor proliferation and metastasis in an autocrine and paracrine manner [32, 34] .
The expression of PDGFRα in breast cancer has been previously associated with tumor progression and a more aggressive phenotype [31] . In this cohort, a positive correlation of PDGFRα with the marker of proliferation, Ki67, was detectable at the point of relapse, supporting the association of PDGFRα signaling with more rapidly progressive breast cancer.
The intracellular non-receptor kinase Abl is well-known for its importance in chronic myeloic leukemia. In this case, Abl is fused to BCR, leading to the activation of the tyrosine kinase domain within Abl [35] . However, recent findings have indicated that activated Abl alone has an important role in solid tumors including breast cancer [20] . Abl is involved in mediating the downstream effects and cellular responses of PDGFR signaling [36] , including PDGFR-mediated proliferation and migration [37] . Moreover, the activation of Abl has been described to promote invasion and an aggressive breast cancer phenotype [21] . To date, only one study has examined the expression of Abl in a cohort of breast cancer patients and described that high expression of Abl in ER+ tumors was associated with higher stage and lymph node involvement [23] . Our observation that Abl expression is increased at the point of relapse on AI treatment supports it having a role in more aggressive behavior. In addition, we showed the up-regulation of Abl correlated with an upregulation of PDGFRα expression, highlighting the likely involvement of this particular signaling pathway in the emergence of recurrent disease.
In this cohort of patients, most, but not all, tumors retained the expression of the ER during the acquisition of resistance to AI treatment [25] . Of note, the changes in ER in this cohort of patients during the development of endocrineresistant breast cancer correlated with changes in Abl expression, supporting potential cross-talk between Abl and ER signaling. In addition, Abl has the ability to phosphorylate not only AIB1, a major coactivator of ER, but also ER itself, resulting in enhanced ER stability, activation and stimulation of cell growth [22, 24] . This novel description of the up-regulation of the PDGFR/ Abl signaling pathway during the development of resistance to AI treatment is of particular clinical importance as there are a number of tyrosine kinase inhibitors available which target PDGFR as well as Abl [38] . In a small neoadjuvant study, the combination of the tyrosine kinase inhibitor imatinib with the AI letrozole has been tested in the treatment of invasive ER-positive breast cancer [39] , resulting in a partial response in the majority of patients. In the metastatic setting, this combination has also shown its efficacy and tolerability [40] . These earlier investigations, together with the current report, argue that further studies to evaluate the clinical importance of targeting the PDGFR/Abl signaling pathway, should be pursued in order to prevent the development of endocrine resistance in breast cancer. Such studies should be accompanied by mandatory tissue collection and analysis to determine whether efficacy segregates with the enhanced activation of the pathway that we have described.
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